Literature DB >> 22580939

Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.

Harvey Chim1, Bryan S Armijo, Erin Miller, Christy Gliniak, Marc A Serret, Arun K Gosain.   

Abstract

OBJECTIVE: To investigate the mechanism of propranolol on regression of infantile hemangiomas.
BACKGROUND: Propranolol has been found to be effective in treatment of severe hemangiomas of infancy. However, its mechanism of action is as yet unknown.
METHODS: Cultured proliferating and involuting hemangioma endothelial cells were treated with varying concentrations of propranolol for up to 4 days. Analysis was performed using cell viability, migration, and tubulogenesis assays, as well as quantitative RT-PCR and flow cytometry. Western blots and ELISA assays were used to assess protein expression.
RESULTS: Treatment with propranolol led to a dose dependent cytotoxic effect in hemangioma endothelial cells with decreased cell viability, migration, and tubulogenesis. This cytotoxic effect was VEGF (vascular endothelial growth factor) dependent, as demonstrated by decreased VEGF, VEGF-R1, and VEGF-R2 production. Decreased signaling through the VEGF pathway resulted in downregulation of PI3/Akt and p38/MAPK activity. Decreased VEGF activity was mediated through the hypoxia inducible factor (HIF)-1α pathway but not through NF-κβ signaling.
CONCLUSIONS: Collectively, these data suggest that propranolol exerts its suppressive effects on hemangiomas through the HIF-1α-VEGF-A angiogenesis axis, with effects mediated through the PI3/Akt and p38/MAPK pathways. These findings provide a plausible mechanism of action of propranolol on regression of infantile hemangiomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580939     DOI: 10.1097/SLA.0b013e318254ce7a

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  45 in total

1.  Propranolol Specifically Suppresses the Viability of Tumorous Schwann Cells Derived from Plexiform Neurofibromas In Vitro.

Authors:  Ziang Zou; Linna Guo; Victor Mautner; Ralf Smeets; Lan Kiuwe; Reinhard E Friedrich
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.

Authors:  Yu-Juan Tang; Zai-Zhong Zhang; Shao-Quan Chen; Shu-Ming Chen; Cheng-Jin Li; Jian-Wei Chen; Bo Yuan; Yin Xia; Lie Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

3.  Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells.

Authors:  Xiaorong Ma; Tinghui Zhao; Tianxiang Ouyang; Shujia Xin; Yueting Ma; Mengling Chang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Repurposing propranolol as an antitumor agent in von Hippel-Lindau disease.

Authors:  Matthew J Shepard; Alejandro Bugarini; Nancy A Edwards; Jie Lu; Qi Zhang; Tianxia Wu; Zhengping Zhuang; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2018-10-01       Impact factor: 5.115

5.  Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma stem cells.

Authors:  Ryan W England; Krista L Hardy; Alex M Kitajewski; Alvin Wong; Jan K Kitajewski; Carrie J Shawber; June K Wu
Journal:  Ann Plast Surg       Date:  2014-09       Impact factor: 1.539

Review 6.  Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.

Authors:  Dayle Rundle-Thiele; Richard Head; Leah Cosgrove; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

7.  Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade.

Authors:  François Moisan; Sandra Oucherif; Priscilla Kaulanjan-Checkmodine; Sorilla Prey; Benoît Rousseau; Marc Bonneu; Stéphane Claverol; Etienne Gontier; Sabrina Lacomme; Lea Dousset; Thierry Couffinhal; Jerome Toutain; Maya Loot; Muriel Cario-André; Marie-Laure Jullié; Christine Léauté-Labrèze; Alain Taieb; Hamid Reza Rezvani
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

8.  Co-suppression of VEGF-A and VEGF-C inhibits development of experimental hemangioma.

Authors:  Chongqing Huang; Jingyong Huang; Guanfeng Yu
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

9.  Artesunate inhibits proliferation and invasion of mouse hemangioendothelioma cells in vitro and of tumor growth in vivo.

Authors:  Ning Wang; Hongxia Chen; Yinping Teng; Xionghui Ding; Huan Wu; Xianqing Jin
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

Review 10.  Beta blockers: an innovation in the treatment of infantile hemangiomas.

Authors:  Shehla Admani; Stephanie Feldstein; Ernesto M Gonzalez; Sheila Fallon Friedlander
Journal:  J Clin Aesthet Dermatol       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.